Drugs / Thymalfasin
Thymalfasin
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04963712 | Sep 2021 → Jul 2022 | HIV infectious disease | Shanghai Public Health Clinical Center | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06821100 | Dec 2024 → Dec 2026 expected | — | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT00001036 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02906163 | Oct 2016 → Dec 2019 | lung cancer | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT02646189 | Aug 2011 → Aug 2013 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT06829355 | Feb → Dec 2025 overdue | colorectal cancer | Beijing Friendship Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06584006 | Sep 2024 → Nov 2027 expected | hematopoietic and lymphoid cell neoplasm, lymphopenia | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06573398 | Sep 2024 → Sep 2025 overdue | pancreatic ductal adenocarcinoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06461910 | Jun 2024 → Jan 2026 overdue | gastric cancer, gastroesophageal junction adenocarcinoma | Zekuan Xu | Recruiting | No outcome recorded |
| Phase 2 | NCT06056804 | Jan → Dec 2024 overdue | — | Beijing Friendship Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05790447 | Apr 2023 → May 2025 | neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT04428008 | Jan 2021 → Jan 2023 | COVID-19 | William B. Ershler, MD | Completed | No outcome recorded |
| Phase 2 | NCT04487444 | Sep 2020 → Feb 2023 | COVID-19 | Rhode Island Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02906150 | Sep 2016 → May 2019 | non-small cell lung carcinoma | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT02542930 | Jan 2016 → Dec 2018 | non-small cell lung carcinoma | Zhejiang Provincial People's Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02545751 | Jan 2016 → Dec 2017 | esophageal cancer | Hangzhou Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02542137 | Sep 2015 → Dec 2018 | small cell lung carcinoma | Zhejiang Provincial People's Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02535988 | Sep 2015 → Jan 2017 | colorectal cancer | Zhejiang Provincial People's Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00082082 | — | hepatocellular carcinoma | SciClone Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00039962 | May 2002 → ? | chronic hepatitis C virus infection | SciClone Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00040027 | Apr 2002 → ? | chronic hepatitis C virus infection | SciClone Pharmaceuticals | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02281266 | Jan 2015 → Jun 2018 | hepatocellular carcinoma | Jia Fan | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07382375 | Dec 2027 expected | aortic disorder | Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06552598 Background | Apr 2024 → Apr 2028 expected | cervical cancer, endometrial cancer | Tongji Hospital | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymalfasin | “Concurrent administration of thymalfasin and rhGM-CSF.” NCT06552598 ↗ |
| Known as | Ta1 | “Thymalfasin (Thymosin alpha 1, Ta1)” NCT02906150 ↗3“Thymalfasin (Thymosin alpha 1, Ta1)” NCT06829355 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT06821100 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT02906163 ↗ |
| Known as | thymosin alpha 1 | “This is a randomized, double-blinded, multicenter trial to determine the effectiveness of thymosin alpha 1 (thymalfasin) 1.6 mg twice weekly plus PEGinterferon alfa-2a 180...” NCT00040027 ↗6“Thymalfasin (Thymosin alpha 1, Ta1)” NCT02906150 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT06829355 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT06821100 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT02906163 ↗ “thymalfasin (thymosin alpha 1)” NCT00039962 ↗ “Thymalfasin (thymosin alpha-1)” NCT00082082 ↗ |
| Known as | ZADAXIN | “ZADAXIN® (trade name; thymalfasin generic; Ta1 for short)” NCT06821100 ↗ |
| Action | Activate | “beneficial clinical effects of Ta1 result from activation of toll-like receptor (TLR) 9” NCT04428008 ↗ |
| Modality | Peptide | “Thymosin alpha 1 (Zadaxin™) is synthetically prepared thymosin alpha 1 polypeptide (28 amino acids, molecular weight 3108)” NCT02646189 ↗ |
| Route | Subcutaneous | “will be administered subcutaneously Thymalfasin at dose of 1.6mg twice a week” NCT02281266 ↗ |